S-1 and Bevacizumab in Treating Patients With Colorectal Cancer That is Recurrent or Cannot Be Removed by Surgery

Sponsor
Osaka Medical College
Study ID
NCT00974389
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
20 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab — BIOLOGICAL
  • tegafur-gimeracil-oteracil potassium — DRUG

Study Details

RATIONALE: Drugs used in chemotherapy, such as S-1, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving S-1 together with bevacizumab may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving S-1 together with bevacizumab works as third-line therapy in treating patients with colorectal cancer that is recurrent or that cannot be removed by surgery.

Key Dates

First listed
Sep 10, 2009
Start date
Jul 31, 2009
Status verified
Sep 2009
Primary completion
Jun 30, 2010

Study Design

Enrollment
40 participants (estimated)
Primary purpose
TREATMENT

Primary Outcome Measure

Disease-control rate

Related Studies